• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Episode 11 - Clinical Guidelines Vital to the Future of MS

Video

Emphasizing the need for clinical guidelines for the treatment of multiple sclerosis (MS), Leslie Fish, PharmD, explains that national guidelines would be helpful when determining the appropriateness of first-line versus second-line therapy.

Dr Fish believes that national guidelines would provide helpful information about treatment effectiveness, and could define which agents should be recommended as second-line therapy based on their side effects.

Gary M. Owens, MD, recognizes that there is no single preferred agent for the treatment of MS and clinicians have fallen into a poor trend as they commonly recommend the most popular options as first-line treatment.

For this reason, there is hesitancy from insurers and clinicians about utilizing newer oral agents for treatment. Dr Owens believes that this issue needs to be addressed, especially as new agents continue to develop.


Related Videos
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.